Neuroblastoma

Chapter

Abstract

Neuroblastoma is a common solid tumor of infancy and childhood. It is uniquely characterized by a distinct natural history and prognosis in infants compared with older children. Whereas older children often experience rapidly progressive disease with a poor prognosis, many infants have indolent tumors that may exhibit only minimal progression over time or may even regress entirely. While the prognosis for infants with neuroblastoma is typically optimistic, patients still require multimodal therapy, ideally provided by institutions with expertise in the treatment of pediatric cancers.

Keywords

Neuroblastoma Newborn Staging Surgical management Outcomes 

References

  1. 1.
    Virchow RLK. Die krankhaften Geschwulste; dreissig Vorlesungen, gehalten wahrend des Wintersemesters 1862–1863 an der Universitat zu Berlin. Berlin: Hirschwald; 1863.Google Scholar
  2. 2.
    Pepper W. A study of congenital sarcoma of the liver and suprarenal. Am J Med Sci. 1901;121:287–99.Google Scholar
  3. 3.
    D’Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971;1:1046–9.Google Scholar
  4. 4.
    Hutchison R. On suprarenal sarcoma in children with metastasis in the skull. Quart J Med. 1907;1:33–41.Google Scholar
  5. 5.
    Wright JH. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med. 1910;12:556–61.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Cushing H, Wolbach SB. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol. 1927;3:203–216.7.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Mason GA, Hart-Mercer J, Millar EJ, Strang LB, Wynne NA. Adrenaline-secreting neuroblastoma in an infant. Lancet. 1957;273:322–5.Google Scholar
  8. 8.
    Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer. 1977;40:2256–63.Google Scholar
  9. 9.
    Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983;305:245–8.Google Scholar
  10. 10.
    Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229–36.Google Scholar
  11. 11.
    Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189–94.Google Scholar
  12. 12.
    Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics. 2008;121:e1470–7.Google Scholar
  13. 13.
    Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer. 2008;112:416–32.Google Scholar
  14. 14.
    Kenney LB, Miller BA, Ries LA, Nicholson HS, Byrne J, Reaman GH. Increased incidence of cancer in infants in the U.S.: 1980–1990. Cancer. 1998;82:1396–400.Google Scholar
  15. 15.
    Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2081–91.Google Scholar
  16. 16.
    Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18:477–86.Google Scholar
  17. 17.
    Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992;52:538–43.Google Scholar
  18. 18.
    Tsuchida Y, Ikeda H, Iehara T, Toyoda Y, Kawa K, Fukuzawa M. Neonatal neuroblastoma: incidence and clinical outcome. Med Pediatr Oncol. 2003;40:391–3.Google Scholar
  19. 19.
    MacCarthy A, Bunch KJ, Fear NT, King JC, Vincent TJ, Murphy MFG. Paternal occupation and neuroblastoma: a case-control study based on cancer registry data for Great Britain 1962–1999. Br J Cancer. 2010;102:615–9.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Moore A, Enquobahrie DA. Paternal occupational exposure to pesticides and risk of neuroblastoma among children: a meta-analysis. Cancer Causes Control. 2011;22:1529–36.Google Scholar
  21. 21.
    Olshan AF, De Roos AJ, Teschke K, Neglia JP, Stram DO, Pollock BH, Castleberry RP. Neuroblastoma and parental occupation. Cancer Causes Control. 1999;10:539–49.Google Scholar
  22. 22.
    Michalek AM, Buck GM, Nasca PC, Freedman AN, Baptiste MS, Mahoney MC. Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol. 1996;143:996–1001.Google Scholar
  23. 23.
    Kerr MA, Nasca PC, Mundt KA, Michalek AM, Baptiste MS, Mahoney MC. Parental occupational exposures and risk of neuroblastoma: a case-control study (United States). Cancer Causes Control. 2000;11:635–43.Google Scholar
  24. 24.
    Bunin GR, Ward E, Kramer S, Rhee CA, Meadows AT. Neuroblastoma and parental occupation. Am J Epidemiol. 1990;131:776–80.Google Scholar
  25. 25.
    Nyari TA, Dickinson HO, Parker L. Childhood cancer in relation to infections in the community during pregnancy and around the time of birth. Int J Cancer. 2003;104:772–7.Google Scholar
  26. 26.
    Bluhm E, McNeil DE, Cnattingius S, Gridley G, Ghormli El L, Fraumeni JF. Prenatal and perinatal risk factors for neuroblastoma. Int J Cancer. 2008;123:2885–90.Google Scholar
  27. 27.
    Johnson KJ, Puumala SE, Soler JT, Spector LG. Perinatal characteristics and risk of neuroblastoma. Int J Cancer. 2008;123:1166–72.Google Scholar
  28. 28.
    McLaughlin CC, Baptiste MS, Schymura MJ, Zdeb MS, Nasca PC. Perinatal risk factors for neuroblastoma. Cancer Causes Control. 2009;20:289–301.Google Scholar
  29. 29.
    Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer. 1986;57:1887–93.Google Scholar
  30. 30.
    Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Brodeur GM. Molecular genetic analysis of familial neuroblastoma. Eur J Cancer. 1997;33:1923–8.Google Scholar
  31. 31.
    Knudson AG, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet. 1972;24:514–32.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Friedman DL, Kadan-Lottick NS, Whitton J, Mertens AC, Yasui Y, Liu Y, Meadows AT, Robison LL, Strong LC. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2005;14:1922–7.Google Scholar
  33. 33.
    Amiel J, Laudier B, Attié-Bitach T, Trang H, de Pontual L, Gener B, Trochet D, Etchevers H, Ray P, Simonneau M, Vekemans M, Munnich A, Gaultier C, Lyonnet S. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet. 2003;33:459–61.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Moore SW. The contribution of associated congenital anomalies in understanding Hirschsprung’s disease. Pediatr Surg Int. 2006;22:305–15.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol. 1997;28:1–5.Google Scholar
  36. 36.
    Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen’s disease: a review of the literature. J Clin Oncol. 1985;3:117–20.Google Scholar
  37. 37.
    DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132:398–400.Google Scholar
  38. 38.
    Knudson AG, Meadows AT. Developmental genetics of neuroblastoma. J Natl Cancer Inst. 1976;57:675–82.Google Scholar
  39. 39.
    Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820–3.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol. 1997;19:93–101.Google Scholar
  41. 41.
    Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311:231–5.Google Scholar
  42. 42.
    Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, Rinaldt V, Vinikoor N, Weisband J. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984;44:5444–9.Google Scholar
  43. 43.
    Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet. 1994;55:334–40.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, Speleman F. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer. 1994;10:103–14.Google Scholar
  45. 45.
    Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–61.Google Scholar
  46. 46.
    Bown N, Lastowska M, Cotterill S, O’Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD. U.K. Cancer Cytogenetics Group and the U.K. Children’s Cancer Study Group 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children’s Cancer Study Group. Med Pediatr Oncol. 2001;36:14–9.Google Scholar
  47. 47.
    Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981;41:4678–86.Google Scholar
  48. 48.
    Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT, Brodeur GM. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 1995;55:4664–9.Google Scholar
  49. 49.
    White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hilliard C. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2–36.3. Proc Natl Acad Sci U S A. 1995;92:5520–4.PubMedPubMedCentralGoogle Scholar
  50. 50.
    White PS, Maris JM, Sulman EP, Jensen SJ, Kyemba SM, Beltinger CP, Allen C, Kramer DL, Biegel JA, Brodeur GM. Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. Eur J Cancer. 1997;33:1957–61.Google Scholar
  51. 51.
    Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001;36:32–6.Google Scholar
  52. 52.
    Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334:225–30.Google Scholar
  53. 53.
    Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schäfer KL, Terpe HJ, Lampert F, Boecker W, Dockhorn-Dworniczak B. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer. 1998;77:2223–9.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Lastowska M, Nacheva E, McGuckin A, Curtis A, Grace C, Pearson A, Bown N. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children’s Cancer Study Group. Genes Chromosomes Cancer. 1997;18:162–9.Google Scholar
  55. 55.
    Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Seeger RC, Gerbing R, Matthay KK, Matise TC, White PS. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol. 2001;36:28–31.Google Scholar
  56. 56.
    Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM. Children’s Oncology Group Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–53.Google Scholar
  57. 57.
    Maris JM, Mossé YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, Glessner JT, Kim C, Frackelton EC, Casalunovo T, Eckert AW, Capasso M, Rappaport EF, McConville C, London WB, Seeger RC, Rahman N, Devoto M, Grant SFA, Li H, Hakonarson H. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–93.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L, Slamon DJ. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res. 1988;271:41–9.Google Scholar
  59. 59.
    Reiter JL, Brodeur GM. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosomes Cancer. 1998;23:134–40.Google Scholar
  60. 60.
    Schwab M, Varmus HE, Bishop JM. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature. 1985;316:160–2.Google Scholar
  61. 61.
    Small MB, Hay N, Schwab M, Bishop JM. Neoplastic transformation by the human gene N-myc. Mol Cell Biol. 1987;7:1638–45.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16:2985–95.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4.Google Scholar
  64. 64.
    Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–6.Google Scholar
  65. 65.
    Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992;52:1364–8.Google Scholar
  66. 66.
    Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328:847–54.Google Scholar
  67. 67.
    Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol. 1994;14:759–67.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Svensson T, Rydén M, Schilling FH, Dominici C, Sehgal R, Ibáñez CF, Kogner P. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma. Eur J Cancer. 1997;33:2058–63.Google Scholar
  69. 69.
    Rydén M, Sehgal R, Dominici C, Schilling FH, Ibáñez CF, Kogner P. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer. 1996;74:773–9.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Yamashiro DJ, Liu XG, Lee CP, Nakagawara A, Ikegaki N, McGregor LM, Baylin SB, Brodeur GM. Expression and function of Trk-C in favourable human neuroblastomas. Eur J Cancer. 1997;33:2054–7.Google Scholar
  71. 71.
    Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73:405–16.Google Scholar
  72. 72.
    Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364–72.Google Scholar
  73. 73.
    Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349–63.Google Scholar
  74. 74.
    Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D’Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874–81.Google Scholar
  75. 75.
    Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.Google Scholar
  76. 76.
    Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson ADJ, Task Force INRG. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Neuroblastoma treatment (PDQ). Bethesda: National Cancer Institute; National Institutes of Health. http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/Page3#Section_14. Accessed Feb. 20, 2012.
  78. 78.
    Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, Task Force INRG. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Moppett J, Haddadin I, Foot AB. Neonatal neuroblastoma. Arch Dis Child Fetal Neonatal Ed. 1999;81:F134–7.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Haas D, Ablin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer. 1988;62:818–25.Google Scholar
  81. 81.
    Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children’s Cancer Group study. J Clin Oncol. 2000;18:1260–8.Google Scholar
  82. 82.
    De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson ADJ. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009;27:1034–40.Google Scholar
  83. 83.
    Rubie H, De Bernardi B, Gerrard M, Cañete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson ADJ, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011;29:449–55.Google Scholar
  84. 84.
    Gigliotti AR, Di Cataldo A, Sorrentino S, Parodi S, Rizzo A, Buffa P, Granata C, Sementa AR, Fagnani AM, Provenzi M, Prete A, D’Ippolito C, Clerico A, Castellano A, Tonini GP, Conte M, Garaventa A, De Bernardi B. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009;45:3220–7.Google Scholar
  85. 85.
    De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer. 1992;70:625–33.Google Scholar
  86. 86.
    Jennings RW, LaQuaglia MP, Leong K, Hendren WH, Adzick NS. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg. 1993;28:1168–74.Google Scholar
  87. 87.
    Acharya S, Jayabose S, Kogan SJ, Tugal O, Beneck D, Leslie D, Slim M. Prenatally diagnosed neuroblastoma. Cancer. 1997;80:304–10.Google Scholar
  88. 88.
    Granata C, Fagnani AM, Gambini C, Boglino C, Bagnulo S, Cecchetto G, Federici S, Inserra A, Michelazzi A, Riccipetitoni G, Rizzo A, Tamaro P, Jasonni V, De Bernardi B. Features and outcome of neuroblastoma detected before birth. J Pediatr Surg. 2000;35:88–91.Google Scholar
  89. 89.
    Nuchtern JG. Perinatal neuroblastoma. Semin Pediatr Surg. 2006;15:10–6.Google Scholar
  90. 90.
    Adams GA, Shochat SJ, Smith EI, Shuster JJ, Joshi VV, Altshuler G, Hayes FA, Nitschke R, McWilliams N, Castleberry RP. Thoracic neuroblastoma: a Pediatric Oncology Group study. J Pediatr Surg. 1993;28:372–7. discussion 377–8Google Scholar
  91. 91.
    Abramson SJ, Berdon WE, Ruzal-Shapiro C, Stolar C, Garvin J. Cervical neuroblastoma in eleven infants—a tumor with favorable prognosis. Clinical and radiologic (US, CT, MRI) findings. Pediatr Radiol. 1993;23:253–7.Google Scholar
  92. 92.
    Haase GM, O’Leary MC, Stram DO, Lukens JN, Seeger RC, Shimada H, Matthay KK. Pelvic neuroblastoma—implications for a new favorable subgroup: a Children’s Cancer Group experience. Ann Surg Oncol. 1995;2:516–23.Google Scholar
  93. 93.
    Nitschke R, Smith EI, Shochat S, Altshuler G, Travers H, Shuster JJ, Hayes FA, Patterson R, McWilliams N. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol. 1988;6:1271–9.Google Scholar
  94. 94.
    Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18:18–26.Google Scholar
  95. 95.
    De Bernardi B, Conte M, Mancini A, Donfrancesco A, Alvisi P, Tomà P, Casale F, Cordero di Montezemolo L, Cornelli PE, Carli M. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1995;13:884–93.Google Scholar
  96. 96.
    La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NKV. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg. 2004;39:412–7.Google Scholar
  97. 97.
    O’Neill JA, Littman P, Blitzer P, Soper K, Chatten J, Shimada H. The role of surgery in localized neuroblastoma. J Pediatr Surg. 1985;20:708–12.Google Scholar
  98. 98.
    Haase GM, Wong KY, deLorimier AA, Sather HN, Hammond GD. Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Pediatr Surg. 1989;24:194–200.Google Scholar
  99. 99.
    Shorter NA, Davidoff AM, Evans AE, Ross AJ, Zeigler MM, O’Neill JA. The role of surgery in the management of stage IV neuroblastoma: a single institution study. Med Pediatr Oncol. 1995;24:287–91.Google Scholar
  100. 100.
    Le Tourneau JN, Bernard JL, Hendren WH, Carcassonne M. Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg. 1985;20:244–9.Google Scholar
  101. 101.
    Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, Ruiz-Jimenez JI, Perez-Hernández R, Cañete A. The role of surgery in stage IV neuroblastoma. J Pediatr Surg. 2002;37:1574–8.Google Scholar
  102. 102.
    Kaneko M, Iwakawa M, Ikebukuro K, Ohkawa H. Complete resection is not required in patients with neuroblastoma under 1 year of age. J Pediatr Surg. 1998;33:1690–4.Google Scholar
  103. 103.
    Guglielmi M, De Bernardi B, Rizzo A, Federici S, Boglino C, Siracusa F, Leggio A, Cozzi F, Cecchetto G, Musi L, Bardini T, Fagnani AM, Bartoli GC, Pampaloni A, Rogers D, Conte M, Milanaccio C, Bruzzi P. Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol. 1996;14:1537–44.Google Scholar
  104. 104.
    Shamberger RC, Smith EI, Joshi VV, Rao PV, Hayes FA, Bowman LC, Castleberry RP. The risk of nephrectomy during local control in abdominal neuroblastoma. J Pediatr Surg. 1998;33:161–4.Google Scholar
  105. 105.
    Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children’s Cancer Group study. J Pediatr Surg. 2004;39(6):931.Google Scholar
  106. 106.
    Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, Cheung NKV, La Quaglia MP. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg. 2011;46:103–7.Google Scholar
  107. 107.
    Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.Google Scholar
  108. 108.
    Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol. 2009;27:1007–13.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NKV. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22:4888–92.Google Scholar
  110. 110.
    Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NKV. Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients. Pediatr Blood Cancer. 2006;46:278–84.Google Scholar
  111. 111.
    Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK. Children’s Oncology Group Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363:1313–23.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Rich BS, McEvoy MP, LaQuaglia MP, Wolden SL. Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma. J Pediatr Surg. 2011;46:97–102.Google Scholar
  113. 113.
    Gillis AM, Sutton E, Dewitt KD, Matthay KK, Weinberg V, Fisch BM, Chan A, Gooding C, Daldrup-Link H, Wara WM, Farmer DL, Harrison MR, Haas-Kogan D. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2007;69:858–64.Google Scholar
  114. 114.
    Kunieda E, Hirobe S, Kaneko T, Nagaoka T, Kamagata S, Nishimura G. Patterns of local recurrence after intraoperative radiotherapy for advanced neuroblastoma. Jpn J Clin Oncol. 2008;38:562–6.Google Scholar
  115. 115.
    Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Children’s Oncology Group Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, Higashigawa M, Tanimura M. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209–14.Google Scholar
  117. 117.
    Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, Bunin G, Levy I, Brossard J, Dougherty G, Tuchman M, Lemieux B. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041–6.Google Scholar
  118. 118.
    Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J, Schwarz K, Treuner J, Zorn U, Michaelis J. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047–53.Google Scholar
  119. 119.
    Laverdière C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, Diller LR, Cheung NK, Wolden S, Robison LL, Sklar CA. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:1131–40.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Levitt GA, Platt KA, De Byrne R, Sebire N, Owens CM. 4S neuroblastoma: the long-term outcome. Pediatr Blood Cancer. 2004;43:120–5.Google Scholar
  121. 121.
    Laverdière C, Cheung NKV, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005;45:324–32.Google Scholar
  122. 122.
    Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172–88.Google Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations